S1196
α-Synuclein A30P human
recombinant, expressed in E. coli, N-terminal histidine tagged, ≥90% (SDS-PAGE), lyophilized powder
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
recombinant
expressed in E. coli
Assay
≥90% (SDS-PAGE)
form
lyophilized powder
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... SNCA(6622)
General description
Alpha synuclein (SNCA) SNCA is a protein made up of 140 amino acids and is coded by 5 exons. It belongs to the synuclein family. SNCA gene is mapped to human chromosome 4q22.1.
Application
α-Synuclein A30P human has been used to inject it stereotaxically into substantia nigra (SN) of mice to study its effects on meningeal lymphatic drainage and its association with Parkinson′s disease (PD).
Biochem/physiol Actions
Alpha synuclein (SNCA) is associated with Lewy bodies′ disease (LBD), Alzheimer′s disease (AD) and muscular system atrophy (MSA).
A point mutation in the α-synuclein gene, Ala30-Pro (A30P), linked to familial Parkinson′s disease.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Mosaicism of alpha-synuclein gene rearrangements: report of two unrelated cases of early-onset parkinsonism.
C Perandones et al.
Parkinsonism & related disorders, 20(5), 558-561 (2014-02-21)
The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication.
Irum Javaid Siddiqui et al.
Scientific reports, 6, 24475-24475 (2016-04-16)
After Alzheimer, Parkinson's disease (PD) is the second most common neurodegenerative disorder. Alpha synuclein (SNCA) is deemed as a major component of Lewy bodies, a neuropathological feature of PD. Five point mutations in SNCA have been reported so far, responsible
Muhammad Abdul Alim et al.
Journal of Alzheimer's disease : JAD, 6(4), 435-442 (2004-09-04)
Alpha-synuclein is a major constituent of pathological intracellular inclusion bodies, a common feature of several neurodegenerative diseases. Two missense mutations in the alpha-synuclein gene have been identified in confirmed autosomal-dominant familial Parkinson's disease, which segregate with the illness. However, the
M H Polymeropoulos et al.
Science (New York, N.Y.), 276(5321), 2045-2047 (1997-06-27)
Parkinson's disease (PD) is a common neurodegenerative disorder with a lifetime incidence of approximately 2 percent. A pattern of familial aggregation has been documented for the disorder, and it was recently reported that a PD susceptibility gene in a large
Wenyan Zou et al.
Translational neurodegeneration, 8, 7-7 (2019-03-15)
Abnormal aggregation of brain α-synuclein is a central step in the pathogenesis of Parkinson's disease (PD), thus, it is reliable to promote the clearance of α-synuclein to prevent and treat PD. Recent studies have revealed an essential role of glymphatic
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service